Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Orthofix Medical (OFIX) Long-Term Debt Issuances (2023 - 2026)

Orthofix Medical (OFIX) reported Long-Term Debt Issuances of $64.0 million for Q1 2026, down 59.38% quarter-over-quarter from $157.6 million in Q4 2024.

Orthofix Medical (OFIX) has 3 years of Long-Term Debt Issuances data on file, last reported at $64.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $64.0 million; the trailing twelve-month figure through Mar 2026 stood at $221.6 million (changed N/A YoY), and the FY2024 full-year result was $197.6 million, up 13.24% from the prior year.
  • Long-Term Debt Issuances for Q1 2026 stood at $64.0 million, down from $157.6 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $157.6 million in Q4 2024 and bottomed at $6.0 million in Q2 2023.
  • A 3-year average of $62.3 million and a median of $45.0 million in 2023 frame the typical range for Long-Term Debt Issuances.
  • Peak annual rise in Long-Term Debt Issuances reached 50.81% in 2024, while the deepest fall reached 11.11% in 2024.
  • Tracing OFIX's Long-Term Debt Issuances over 3 years: stood at $104.5 million in 2023, then surged by 50.81% to $157.6 million in 2024, then sank by 59.38% to $64.0 million in 2026.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $64.0 million, $157.6 million, and $40.0 million for Q1 2026, Q4 2024, and Q1 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Orthofix Medical 375.38 Mn 254.51 Mn 139.55 Mn 64.03 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 64.03 Mn
Mar 31, 2026 64.03 Mn
Dec 31, 2024 157.60 Mn
Dec 31, 2024 157.60 Mn
Mar 31, 2024 40.00 Mn
Mar 31, 2024 40.00 Mn
Dec 31, 2023 104.50 Mn
Dec 31, 2023 104.50 Mn
Sep 30, 2023 19.00 Mn
Sep 30, 2023 19.00 Mn
Jun 30, 2023 6.00 Mn
Jun 30, 2023 6.00 Mn
Mar 31, 2023 45.00 Mn
Mar 31, 2023 45.00 Mn